Key Drivers
- Margin expansion
- Strong cash conversion
- Higher leverage
AIAI Summary
Humana is evolving from a simple managed-care recovery into a more diversified health-services story, but the stock's real upside still hinges on one thing: MCR normalizing into the 87%–88% range, because if that doesn't happen, the recent rally is more likely an extended bounce than a durable re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin expansion
- •Strong cash conversion
- •Higher leverage
HUM posted a strong Q1 2026 with higher margins and much stronger cash flow, but rising leverage, still-thin operating margins, and a richer valuation temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Strong uptrend
- •Resistance test
- •Overbought pullback
HUM has surged sharply over the last month and remains in a strong uptrend above key support, but its pullback from $409.42 suggests near-term overbought conditions and possible consolidation unless it breaks resistance.
Pulled back from $409.42 to $396.75 after a late-June high, signaling profit-taking and short-term overstretch
Sentiment & News
Key News Insights:
- •CenterWell Growth
- •Gentiva Exit
- •Legal Scrutiny
Humana is sharpening its pivot toward CenterWell-led growth and margin recovery while simplifying the portfolio via its Gentiva exit, but ongoing legal scrutiny remains a near-term overhang.
The headlines support a stronger long-term growth and margin narrative for HUM, but litigation risk could cap near-term upside until the investigations clear
Similar Companies in Healthcare
Other companies in the same sector with AI ratings